BeiGene Reports BTK Inhibitor Posts Better Results than the Competition

Beijing 's BeiGene presented positive interim results from Phase III trial that compared its BTK candidate to AbbVie's Imbruvica (ibrutinib). In the trial, BeiGene's Brukinsa® (zanubrutinib) produced a 78.3% overall response rate compared to imbrutinib's 62.5%. The trial was conducted in adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The progression free survival rate at 12 months was 94.9% in the Brukinsa arm, compared to 84.0% in the ibrutinib arm. More details.... Stock Symbol: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //